carbamazepine has been researched along with Depression in 57 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We carried out a systematic search for publications in English and Russian on the safety and efficacy of CMZ in depressive disorders of different etiologies in the PubMed, Web of Science, Springer, Clinical Keys, Google Schooler, E-Library databases using keywords and combined word searches (carbamazepine, COVID-19, depression, epilepsy, post-COVID-syndrome) for the period from January 01,2020 to June 10, 2022." | 9.22 | Possible Clinical and Pharmacogenetic Predictors of the Efficacy and Safety of Carbamazepine in Post-COVID-19 Depression. ( Cumming, P; Davydkin, I; Fedyashov, I; Gayduk, A; Nasyrova, R; Shnayder, N; Smirnova, D; Strelnik, A; Vaiman, E, 2022) |
| "The aim of this study was to evaluate the safety and efficacy of extended release carbamazepine (CBZ-ER) monotherapy in the treatment of pediatric bipolar disorder (BD)." | 9.14 | A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. ( Aleardi, M; Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Walls, S; Williams, C; Wozniak, J, 2010) |
| "The therapeutic effects of lithium in depression are reviewed." | 8.77 | Lithium in depression: a review of the antidepressant and prophylactic effects of lithium. ( Johnson, GF, 1987) |
| "Lithium (LiCl) and carbamazepine (CBZ), the common mood stabilizers, are thought to be effective treatments for bipolar disorder." | 7.79 | Effects of lithium and carbamazepine on spatial learning and depressive behavior in a rat model of bipolar disorder induced by ouabain. ( Huang, AC; Huang, CL; Wang, CC; Wang, EN; Wang, YC, 2013) |
| " We present a case of serotonin syndrome, which was precipitated by this medicine in a patient who had been predisposed by long-term treatment with sertraline, a selective serotonin reuptake inhibitor." | 7.78 | Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor. ( Dardis, C; Ly, V; Omoregie, E, 2012) |
| "The use of carbamazepine has been reported to be an effective treatment for severe depression." | 7.74 | Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? ( Akiyama, K; Araki, H; Gomita, Y; Kawasaki, H; Kitagawa, K; Kitamura, Y; Sendo, T; Shibata, K; Suemaru, K, 2008) |
| "Essential erythermalgia is a rare acrosyndrome that is difficult to treat." | 5.35 | [Primary erythermalgia: efficacy of oxcarbazepine]. ( Benchikhi, H; Hmamouchi, B; Moutawakil, B; Skali Dahbi, S; Zouhair, K, 2009) |
| "We carried out a systematic search for publications in English and Russian on the safety and efficacy of CMZ in depressive disorders of different etiologies in the PubMed, Web of Science, Springer, Clinical Keys, Google Schooler, E-Library databases using keywords and combined word searches (carbamazepine, COVID-19, depression, epilepsy, post-COVID-syndrome) for the period from January 01,2020 to June 10, 2022." | 5.22 | Possible Clinical and Pharmacogenetic Predictors of the Efficacy and Safety of Carbamazepine in Post-COVID-19 Depression. ( Cumming, P; Davydkin, I; Fedyashov, I; Gayduk, A; Nasyrova, R; Shnayder, N; Smirnova, D; Strelnik, A; Vaiman, E, 2022) |
| "The aim of this study was to evaluate the safety and efficacy of extended release carbamazepine (CBZ-ER) monotherapy in the treatment of pediatric bipolar disorder (BD)." | 5.14 | A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. ( Aleardi, M; Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Walls, S; Williams, C; Wozniak, J, 2010) |
| "The therapeutic effects of lithium in depression are reviewed." | 4.77 | Lithium in depression: a review of the antidepressant and prophylactic effects of lithium. ( Johnson, GF, 1987) |
| "Carbamazepine and topiramate both have established potentials for causing teratogenesis, and it is possible that replacement of carbamazepine with a less teratogenic AED, for example levetiracetam, might result in any subsequent depression that occurs in pregnancy being inappropriately attributed to the newly introduced agent." | 3.96 | Antiepileptic drugs and depression during pregnancy in women with epilepsy. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Horgan, D; Lander, CM; Mitchell, J; O'Brien, TJ; Vajda, FJE, 2020) |
| "These results demonstrate a behaviourally effective oral and chronic regimen for carbamazepine with mood stabilising-like activity in a standard model for mania-like behaviour and two standard models for depression-like behaviour." | 3.80 | Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice. ( Agam, G; Belmaker, RH; Einat, H; Kara, NZ; Karpel, O; Toker, L, 2014) |
| "Lithium (LiCl) and carbamazepine (CBZ), the common mood stabilizers, are thought to be effective treatments for bipolar disorder." | 3.79 | Effects of lithium and carbamazepine on spatial learning and depressive behavior in a rat model of bipolar disorder induced by ouabain. ( Huang, AC; Huang, CL; Wang, CC; Wang, EN; Wang, YC, 2013) |
| " We present a case of serotonin syndrome, which was precipitated by this medicine in a patient who had been predisposed by long-term treatment with sertraline, a selective serotonin reuptake inhibitor." | 3.78 | Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor. ( Dardis, C; Ly, V; Omoregie, E, 2012) |
| " However, zonisamide- and carbamazepine-treated animals had IT values similar to those of controls, but only zonisamide significantly decreased absence seizure development." | 3.77 | Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. ( Citraro, R; Constanti, A; De Fazio, S; De Sarro, G; Di Paola, ED; Perrota, I; Perrotta, I; Russo, E; Scicchitano, F, 2011) |
| " Although a lymphocyte stimulation test was positive only for acetaminophen, he took other agents including carbamazepine for his depression." | 3.76 | Toxic epidermal necrolysis with prominent facial pustules: a case with reactivation of human herpesvirus 7. ( Honma, M; Iinuma, S; Iizuka, H; Ishida-Yamamoto, A; Komatsu, S; Shibuya, T; Takahashi, I; Tobisawa, S, 2010) |
| "A 43-year-old woman was being treated with oxcarbazepine for depression and was started on lamotrigine 2 weeks prior to her presentation." | 3.74 | Lamotrigine-associated reversible severe hepatitis: a case report. ( Olson, KR; Su-Yin, AN; Tai, WW, 2008) |
| "The use of carbamazepine has been reported to be an effective treatment for severe depression." | 3.74 | Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? ( Akiyama, K; Araki, H; Gomita, Y; Kawasaki, H; Kitagawa, K; Kitamura, Y; Sendo, T; Shibata, K; Suemaru, K, 2008) |
| "The effect of oxcarbazepine was evaluated in two tests of depression (forced swimming and learned helplessness) and in the open-field test." | 3.70 | The effect of oxcarbazepine on behavioural despair and learned helplessness. ( Andreatini, R; Beijamini, V; Joca, SR; Skalisz, LL, 1998) |
| "Levetiracetam was the drug of choice in treating patients with hepatic failure, or who have undergone organ transplantation." | 2.55 | Epilepsy treatment in adults and adolescents: Expert opinion, 2016. ( Chimato, N; Frank, RD; Karceski, SC; Shih, JJ; Vargas, E; Whitlock, JB, 2017) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| "All patients ≥16years of age with epilepsy for ≥12months were routinely asked to complete the Liverpool Adverse Event Profile (LAEP) just before their appointment." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| "Essential erythermalgia is a rare acrosyndrome that is difficult to treat." | 1.35 | [Primary erythermalgia: efficacy of oxcarbazepine]. ( Benchikhi, H; Hmamouchi, B; Moutawakil, B; Skali Dahbi, S; Zouhair, K, 2009) |
| " Diluted charcoal was administered through a nasogastric tube at a dose of 1 g/kg every 4 h, and a saline cathartic at the same dosage was administered every 12 h." | 1.29 | Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. ( Escalante-Galindo, P; Flores-Alvarez, E; Montoya-Cabrera, MA; Ruiz-Gómez, A; Sauceda-García, JM, 1996) |
| "Withdrawal symptoms were assessed every third day during the study period." | 1.28 | Treatment of benzodiazepine withdrawal symptoms with carbamazepine. ( Apelt, S; Bronisch, T; Emrich, HM; Garcia-Borreguero, D; Yassouridis, A, 1991) |
| "Carbamazepine effectively treated the depression and mania was avoided." | 1.27 | Carbamazepine in bipolar-depressed disorder complicated by tricyclic antidepressant switching: case report. ( Finkel, JA; Nurnberg, HG, 1985) |
| " The importance of adequate dosage and duration in any treatment trial are emphasized, and the evidence in support of combined antidepressants, lithium-antidepressant combinations, the addition of triiodothyronine or tryptophan, the use of anticonvulsants, and the use of vanadium inactivators, is evaluated." | 1.27 | Pharmacological strategies in depression. ( Barnes, TR; Katona, CL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (28.07) | 18.7374 |
| 1990's | 11 (19.30) | 18.2507 |
| 2000's | 10 (17.54) | 29.6817 |
| 2010's | 15 (26.32) | 24.3611 |
| 2020's | 5 (8.77) | 2.80 |
| Authors | Studies |
|---|---|
| Vaiman, E | 1 |
| Gayduk, A | 1 |
| Strelnik, A | 1 |
| Smirnova, D | 1 |
| Davydkin, I | 1 |
| Fedyashov, I | 1 |
| Cumming, P | 1 |
| Shnayder, N | 1 |
| Nasyrova, R | 1 |
| Schmitz, B | 1 |
| Dimova, S | 1 |
| Zhang, Y | 1 |
| Chellun, D | 1 |
| De Backer, M | 1 |
| Gasalla, T | 1 |
| Hamed, SA | 1 |
| Attiah, FA | 1 |
| Gabra, RH | 1 |
| Sherif, TK | 1 |
| Ajaman, M | 1 |
| Naserzadeh, R | 1 |
| Ghorbanzadeh, B | 1 |
| Vajda, FJE | 1 |
| O'Brien, TJ | 1 |
| Graham, JE | 1 |
| Hitchcock, AA | 1 |
| Mitchell, J | 1 |
| Horgan, D | 1 |
| Lander, CM | 1 |
| Eadie, MJ | 1 |
| Albright, A | 1 |
| Way, RT | 1 |
| Häfele, CA | 1 |
| Freitas, MP | 1 |
| Gervini, BL | 1 |
| de Carvalho, RM | 1 |
| Rombaldi, AJ | 1 |
| Silva, EF | 1 |
| Silva, AI | 1 |
| Asth, L | 1 |
| Souza, LS | 1 |
| Zaveri, NT | 1 |
| Guerrini, R | 1 |
| Calo', G | 1 |
| Ruzza, C | 1 |
| Gavioli, EC | 1 |
| Tobin, WO | 1 |
| Wang, YC | 1 |
| Wang, EN | 1 |
| Wang, CC | 1 |
| Huang, CL | 1 |
| Huang, AC | 1 |
| Kara, NZ | 1 |
| Karpel, O | 1 |
| Toker, L | 1 |
| Agam, G | 1 |
| Belmaker, RH | 1 |
| Einat, H | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Gorwood, P | 1 |
| Richard-Devantoy, S | 1 |
| Sentissi, O | 1 |
| Le Strat, Y | 1 |
| Olié, JP | 1 |
| Wieshmann, UC | 1 |
| Baker, G | 1 |
| Shih, JJ | 1 |
| Whitlock, JB | 1 |
| Chimato, N | 1 |
| Vargas, E | 1 |
| Karceski, SC | 1 |
| Frank, RD | 1 |
| Juruena, MF | 1 |
| Ottoni, GL | 1 |
| Machado-Vieira, R | 1 |
| Carneiro, RM | 1 |
| Weingarthner, N | 1 |
| Marquardt, AR | 1 |
| Fleig, SS | 1 |
| Broilo, L | 1 |
| Busnello, EA | 1 |
| Su-Yin, AN | 1 |
| Tai, WW | 1 |
| Olson, KR | 1 |
| Skali Dahbi, S | 1 |
| Zouhair, K | 1 |
| Moutawakil, B | 1 |
| Hmamouchi, B | 1 |
| Benchikhi, H | 1 |
| Joshi, G | 1 |
| Wozniak, J | 1 |
| Mick, E | 1 |
| Doyle, R | 1 |
| Hammerness, P | 1 |
| Georgiopoulos, A | 1 |
| Kotarski, M | 1 |
| Aleardi, M | 1 |
| Williams, C | 1 |
| Walls, S | 1 |
| Biederman, J | 1 |
| Barbakadze, M | 1 |
| Bilanishvili, I | 1 |
| Chkhetiani, M | 1 |
| Khizanishvili, N | 1 |
| Koreli, A | 1 |
| Honma, M | 1 |
| Tobisawa, S | 1 |
| Iinuma, S | 1 |
| Shibuya, T | 1 |
| Komatsu, S | 1 |
| Takahashi, I | 1 |
| Ishida-Yamamoto, A | 1 |
| Iizuka, H | 1 |
| Russo, E | 1 |
| Citraro, R | 1 |
| Scicchitano, F | 1 |
| De Fazio, S | 1 |
| Perrotta, I | 1 |
| Perrota, I | 1 |
| Di Paola, ED | 1 |
| Constanti, A | 1 |
| De Sarro, G | 1 |
| Dardis, C | 1 |
| Omoregie, E | 1 |
| Ly, V | 1 |
| Neumann, NU | 1 |
| Bretschneider, S | 1 |
| Bullacher, Ch | 1 |
| Frasch, K | 1 |
| Hess, R | 1 |
| Wittek, R | 1 |
| Krüger, TH | 1 |
| Brink, P | 1 |
| Goebel, MU | 1 |
| Schiffer, B | 1 |
| Schedlowski, M | 1 |
| Hartmann, U | 1 |
| Schneider, U | 1 |
| Kłak, K | 1 |
| Pałucha, A | 1 |
| Brański, P | 1 |
| Sowa, M | 1 |
| Pilc, A | 1 |
| Soyka, M | 1 |
| Roesner, S | 1 |
| Tölle, T | 1 |
| Dukes, E | 1 |
| Sadosky, A | 1 |
| Kitamura, Y | 1 |
| Akiyama, K | 1 |
| Kitagawa, K | 1 |
| Shibata, K | 1 |
| Kawasaki, H | 1 |
| Suemaru, K | 1 |
| Araki, H | 1 |
| Sendo, T | 1 |
| Gomita, Y | 1 |
| Pisani, F | 2 |
| Narbone, MC | 1 |
| Fazio, A | 2 |
| Crisafulli, P | 1 |
| Primerano, G | 1 |
| D'Agostino, AA | 1 |
| Oteri, G | 1 |
| Di Perri, R | 1 |
| Borg, V | 1 |
| Kranzler, HR | 1 |
| Bauer, LO | 1 |
| Hersh, D | 1 |
| Klinghoffer, V | 1 |
| Montoya, ID | 1 |
| Levin, FR | 1 |
| Fudala, PJ | 1 |
| Gorelick, DA | 1 |
| Spina, E | 1 |
| Avenoso, A | 1 |
| Pollicino, AM | 1 |
| Caputi, AP | 1 |
| Patel, SV | 1 |
| Tariot, PN | 1 |
| Asnis, J | 1 |
| Ford, N | 1 |
| Montoya-Cabrera, MA | 1 |
| Sauceda-García, JM | 1 |
| Escalante-Galindo, P | 1 |
| Flores-Alvarez, E | 1 |
| Ruiz-Gómez, A | 1 |
| Beijamini, V | 1 |
| Skalisz, LL | 1 |
| Joca, SR | 1 |
| Andreatini, R | 1 |
| Gorsky, BH | 1 |
| Ballenger, JC | 1 |
| Post, RM | 3 |
| Garcia-Borreguero, D | 1 |
| Bronisch, T | 1 |
| Apelt, S | 1 |
| Yassouridis, A | 1 |
| Emrich, HM | 1 |
| Nygaard, TG | 1 |
| Marsden, CD | 1 |
| Fahn, S | 1 |
| Altshuler, LL | 2 |
| Ketter, TA | 1 |
| Denicoff, K | 1 |
| Weiss, SR | 1 |
| Devinsky, O | 1 |
| Theodore, W | 1 |
| Kostiukova, EG | 1 |
| Johnson, GF | 1 |
| Herrera, JM | 1 |
| Sramek, JJ | 1 |
| Costa, JF | 1 |
| Chrousos, GA | 1 |
| Cowdry, R | 1 |
| Schuelein, M | 1 |
| Abdul-Rahim, AS | 1 |
| Matsuo, V | 1 |
| Currie, JN | 1 |
| Hudson, JI | 1 |
| Pope, HG | 1 |
| Jonas, JM | 1 |
| Yurgelun-Todd, D | 1 |
| Nurnberg, HG | 1 |
| Finkel, JA | 1 |
| Katona, CL | 1 |
| Barnes, TR | 1 |
| Wieck, HH | 1 |
| Myrstener, A | 1 |
| Redpath, TH | 1 |
| Gayford, JJ | 1 |
| Inose, T | 1 |
| Hirata, I | 1 |
| Kawajiwara, A | 1 |
| Iwata, T | 1 |
| Tano, T | 1 |
| Suwa, K | 1 |
| Toru, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial[NCT02235064] | 2 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Low recruitment, completion of funding cycle) | |||
| A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596] | Phase 2 | 33 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Monitoring of Seizures, EEG and Serum Antiepileptic Drug Concentrations in Patients With Uncontrolled Epilepsy[NCT00001149] | 900 participants | Observational | 1975-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 1 |
"Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment~0 = No postpartum depression up to 12 weeks following discharge from hospital~1 = Postpartum depression up to 12 weeks following discharge from hospital" (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 4734 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 3033 |
| Placebo | 2750 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 3685 |
Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.005 |
| Placebo | 0.172 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.67 |
| Placebo | 1.23 |
Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.113 |
| Placebo | 0.225 |
Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.386 |
| Placebo | 0.664 |
"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.256 |
| Placebo | -0.046 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.10 |
| Placebo | 1.50 |
Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.227 |
| Placebo | -0.170 |
Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.54 |
| Placebo | -0.06 |
"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.087 |
| Placebo | 0.405 |
Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.140 |
| Placebo | 0.071 |
8 reviews available for carbamazepine and Depression
| Article | Year |
|---|---|
Possible Clinical and Pharmacogenetic Predictors of the Efficacy and Safety of Carbamazepine in Post-COVID-19 Depression.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Carbamazepine; COVID-19; COVID-19 Drug Trea | 2022 |
Management of Multiple Sclerosis Symptoms and Comorbidities.
Topics: Anticonvulsants; Carbamazepine; Cognitive Dysfunction; Comorbidity; Depression; Disease Management; | 2019 |
Epilepsy treatment in adults and adolescents: Expert opinion, 2016.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Depression; Double-Blind Method; Dru | 2017 |
[Persisting deficits after severe depression].
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Cognition Disor | 2003 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Ani | 2006 |
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Breast Feed | 2008 |
Antiepileptic drugs in affective illness. Clinical and theoretical implications.
Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Bipolar Disorder; Carbamazepine; Depression; Drug T | 1991 |
Lithium in depression: a review of the antidepressant and prophylactic effects of lithium.
Topics: Antidepressive Agents; Carbamazepine; Depression; Dose-Response Relationship, Drug; Drug Therapy, Co | 1987 |
9 trials available for carbamazepine and Depression
| Article | Year |
|---|---|
Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Delayed-Action Preparations; Depression; Doubl | 2020 |
Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depression; Double-Blind Method; Drug Resi | 2009 |
A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder.
Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Body Weight; Carb | 2010 |
[Clinical trial of Tegretol and Anafranil/Sinequan in alcohol abstinence symptoms].
Topics: Alcoholism; Carbamazepine; Clinical Trials as Topic; Clomipramine; Depression; Double-Blind Method; | 1980 |
Carbamazepine treatment of cocaine dependence: a placebo-controlled trial.
Topics: Adolescent; Adult; Alcoholism; Anticonvulsants; Anxiety; Carbamazepine; Cocaine; Comorbidity; Depres | 1995 |
Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence.
Topics: Adult; Ambulatory Care; Anticonvulsants; Carbamazepine; Cocaine; Depression; Dose-Response Relations | 1995 |
Carbamazepine coadministration with fluoxetine or fluvoxamine.
Topics: Adult; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Epilepsy, Complex Pa | 1993 |
Therapeutic effects of carbamazepine in affective illness: a preliminary report.
Topics: Adult; Affective Symptoms; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depression; Do | 1978 |
[Carbamazepine treatment of epileptic psychosis].
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Depression; Dibenzazepi | 1968 |
40 other studies available for carbamazepine and Depression
| Article | Year |
|---|---|
Sexual functions in women with focal epilepsy: Relationship to demographic, clinical, hormonal and psychological variables.
Topics: Adult; Anticonvulsants; Anxiety; Carbamazepine; Depression; Egypt; Epilepsy, Frontal Lobe; Epilepsy, | 2020 |
Pharmacological evaluation of NO/cGMP/KATP channels pathway in the antidepressant-like effect of carbamazepine in mice.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Carbamazepine; Cyclic GMP; Depression; Disease Mode | 2021 |
Antiepileptic drugs and depression during pregnancy in women with epilepsy.
Topics: Adult; Anticonvulsants; Australia; Carbamazepine; Depression; Epilepsy; Female; Humans; Levetiraceta | 2020 |
Lithium toxicity and prolonged delirium.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepine; Delirium; Depression; Dose | 2017 |
Who are the individuals diagnosed with epilepsy using the Public Health System in the city of Pelotas, southern Brazil?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Anxiety; Brazil; Carbamazepine; Child; Cross-Sectional Stu | 2018 |
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Topics: Aggression; Agonistic Behavior; Animals; Anxiety; Bipolar Disorder; Carbamazepine; Cycloheptanes; De | 2019 |
Effects of lithium and carbamazepine on spatial learning and depressive behavior in a rat model of bipolar disorder induced by ouabain.
Topics: Animals; Bipolar Disorder; Carbamazepine; Depression; Disease Models, Animal; Learning; Lithium; Mal | 2013 |
Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice.
Topics: Administration, Oral; Affect; Animals; Bipolar Disorder; Carbamazepine; Depression; Disease Models, | 2014 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
The number of past manic episodes is the best predictor of antidepressant-emergent manic switch in a cohort of bipolar depressed patients.
Topics: Adult; Affect; Aged; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depre | 2016 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Lamotrigine-associated reversible severe hepatitis: a case report.
Topics: Adult; Anticonvulsants; Antimanic Agents; Carbamazepine; Chemical and Drug Induced Liver Injury; Dep | 2008 |
[Primary erythermalgia: efficacy of oxcarbazepine].
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Carbamazepine; Depression; Erythromelalgia; Foot | 2009 |
Influence of carbamazepine on kindling grades in depressive and non-depressive rats.
Topics: Animals; Anticonvulsants; Carbamazepine; Depression; Disease Models, Animal; Electric Stimulation; E | 2010 |
Toxic epidermal necrolysis with prominent facial pustules: a case with reactivation of human herpesvirus 7.
Topics: Acetaminophen; Acute Generalized Exanthematous Pustulosis; Adult; Anti-Inflammatory Agents; Antidepr | 2010 |
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Depression; Dose-Response Relationship, Drug; Electr | 2011 |
Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor.
Topics: Aged, 80 and over; Analgesics; Antihypertensive Agents; Atrial Fibrillation; Bronchodilator Agents; | 2012 |
Endocrine alterations during a detoxification treatment with carbamazepine in male alcoholics.
Topics: Adult; Aged; Alcoholism; Androgens; Carbamazepine; Chronic Disease; Depression; Estradiol; Ethanol; | 2006 |
Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats.
Topics: Allosteric Site; Animals; Antidepressive Agents; Behavior, Animal; Benzopyrans; Brain; Carbamazepine | 2007 |
Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries.
Topics: Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antidepressive Agents; Anxiety; Carbamazep | 2006 |
Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors?
Topics: Adrenocorticotropic Hormone; Amphetamines; Animals; Antidepressive Agents; Carbamazepine; Depression | 2008 |
Effect of viloxazine on serum carbamazepine levels in epileptic patients.
Topics: Adult; Carbamazepine; Depression; Drug Interactions; Epilepsy; Female; Humans; Male; Middle Aged; Mo | 1984 |
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention; Carbamazepine; Depressi | 1996 |
The use of anticonvulsants in posttraumatic stress disorder: case study and overview.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Humans; Male; Reflex, Startle; Stress Disorders, | 1996 |
Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Cardiovascular System; Charcoal; Depression; Drug Overdo | 1996 |
The effect of oxcarbazepine on behavioural despair and learned helplessness.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Depression; Disease Models, Animal; Helpl | 1998 |
Chronic pain: a management plan based on experiences in a pain clinic.
Topics: Behavior Therapy; Carbamazepine; Chronic Disease; Depression; Electric Stimulation Therapy; Humans; | 1979 |
Treatment of benzodiazepine withdrawal symptoms with carbamazepine.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Arousal; Carbamazepine; Crisis Intervention; Depression; Diazep | 1991 |
Dopa-responsive dystonia: long-term treatment response and prognosis.
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Depression; Dihydroxyphenylalanine; Disab | 1991 |
Depression, anxiety, and temporal lobe epilepsy. Laterality of focus and symptoms.
Topics: Adult; Analysis of Variance; Anxiety; Carbamazepine; Depression; Epilepsy, Temporal Lobe; Female; Fu | 1990 |
[Comparative features of the preventive action of carbamazepine and lithium carbonate in affective and schizoaffective psychoses].
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Carbamazepine; Depression; Drug Evaluation; | 1989 |
Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia.
Topics: Adult; Analysis of Variance; Carbamazepine; Chronic Disease; Depression; Humans; Irritable Mood; Mal | 1987 |
Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.
Topics: Adolescent; Adult; Carbamazepine; Depression; Female; Humans; Nystagmus, Pathologic; Seizures; Visio | 1987 |
Treatment of anorexia nervosa with antidepressants.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents; Antidepressive Agents, Tricyclic; Body W | 1985 |
Carbamazepine in bipolar-depressed disorder complicated by tricyclic antidepressant switching: case report.
Topics: Adult; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Depression; Female; Humans | 1985 |
Pharmacological strategies in depression.
Topics: Antidepressive Agents, Tricyclic; Carbamazepine; Depression; Drug Administration Schedule; Drug Ther | 1985 |
[Headache. Diagnosis and therapy in general practice].
Topics: Carbamazepine; Chlorpromazine; Depression; Ergotamine; Giant Cell Arteritis; Headache; Humans; Migra | 1974 |
The side effects of carbamazepine therapy.
Topics: Ataxia; Carbamazepine; Depression; Dibenzazepines; Female; Humans; Leukocyte Count; Male; Middle Age | 1968 |
[Depressive condition with electroencephalographic abnormalities--contribution to differential diagnosis of endogenous depression].
Topics: Adolescent; Adult; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Depression; Diagnosis, Di | 1969 |
A case of periodic somnolence whose sleep was induced by glucose.
Topics: Adolescent; Adult; Carbamazepine; Depression; Electroencephalography; Food Preferences; Glucose; Hum | 1969 |